Trial · NCT06351150
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of subjects with blood pressure response at 3 hours after administration of study drug | 3 hours after dose | Defined as MAP ≥ 75 mmHg or MAP increase ≥ 10 mmHg from baseline compared to baseline without an increase in the dose of background vasoactive agents |
| Secondary | Sequential Organ Failure Assessment (SOFA) total score | 48 hours after dose | Change from baseline in Sequential Organ Failure Assessment (SOFA) total score. The SOFA score evaluates organ failure according to the conditions of respiratory, blood, liver, cardiovascular, central nervous, kidney and other systems, is scored from 0 to 4, with a higher score representing more severe failure. |
| Secondary | Cardiovascular SOFA subscore | 48 hours after dose | Change from baseline in Sequential Organ Failure Assessment (SOFA) subscore. The SOFA score evaluates organ failure according to the conditions of respiratory, blood, liver, cardiovascular, central nervous, kidney and other systems, is scored from 0 to 4, with a higher score representing more severe failure. |
| Secondary | Mortality at Day 7 | Day 7 after dose | All-cause mortality of subject at Day 7 |
| Secondary | Mortality at Day 28 | Day 28 after dose | All-cause mortality of subject at Day 28 |
| Secondary | Proportion of subjects with blood pressure response at 1 hour after administration | 1 hour after dose | Defined as MAP ≥ 75 mmHg or MAP increase ≥ 10 mmHg from baseline compared to baseline without an increase in the dose of background vasoactive agents |
| Secondary | Proportion of subjects with blood pressure response at 2 hours after administration | 2 hours after dose | Defined as MAP ≥ 75 mmHg or MAP increase ≥ 10 mmHg from baseline compared to baseline without an increase in the dose of background vasoactive agents |
| Secondary | Change in background vasoactive agent dose from 0 to 48 hours | 48 hours after dose | Change in background vasoactive dose from baseline to 48 hours after dose |
| Secondary | Absolute change in blood lactate from 0 to 3 hours | 3 hours after dose | Absolute change in blood lactate from 0 to 3 hours |
| Secondary | Absolute change in blood lactate from 3 to 48 hours | 3 to 48 hours after dose | Absolute change in blood lactate from 3 to 48 hours |
| Secondary | Absolute change in heart rate from 0 to 3 hours | 3 hours after dose | Absolute change in heart rate from 0 to 3 hours |
| Secondary | Absolute change in heart rate from 3 to 48 hours | 3 to 48 hours after dose | Absolute change in heart rate from 3 to 48 hours |
| Secondary | Adverse events (AE) | From drug administration to the end of the study, a total of 28 days | Incidence and severity of adverse events (AE) |
| Secondary | Serious adverse events (SAE) | From drug administration to the end of the study, a total of 28 days | Incidence and severity of serious adverse events (SAE) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06351150/registered